An activist holds a placard opposing any post-Brexit U.S. market access to Britain's National Health Service (NHS) during a demonstration in Trafalgar Square, London. (Photo: David Cliff/SOPA Images/LightRocket via Getty Images)
Documents Reveal 'Toxic Trump-Johnson Deal' Post-Brexit Would Allow US Pharma Industry to Send NHS Drug Prices Skyrocketing
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour leader Jeremy Corbyn said.
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."
We are at a crossroads
This country and this world are at a monumental crossroads. In a few short weeks, US voters will have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. Our Fall Campaign is underway, and we need your help. To power our newsroom through the rest of the year, we need to raise $125,000 by midnight on October 31. So if you share our vision, please contribute whatever you can to sustain our work. |
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."
Brexit and Tory critics in the U.K. on Wednesday called on voters to reject the Conservatives in the upcoming general election in light of new confirmation that U.S. pharmaceutical companies would be given free reign to drive up drug prices in a post-Brexit trade deal should the Conservatives retain control of the government.
Documents obtained Tuesday by the Daily Mirror reveal that the U.S. pharmaceutical industry is lobbying trade negotiators to allow for an open drug market in the U.K. in the potential trade deal President Donald Trump plans to forge with the Tories if Prime Minister Boris Johnson and his party win on Dec. 12.
"Boris Johnson has put our NHS up for sale. It's time to save the NHS from a U.S. trade deal."
--The Labour Party
The "predatory" industry, as the Mirror described Big Pharma, is hoping for one-on-one negotiations with the U.K. after Brexit, away from the E.U., believing the U.K. on its own will be likely to allow U.S. companies to set drug prices.
"Concerns about potential impacts on Britain's National Health Service are being aired," reads the document, titled Services Priorities for a Future U.S.-U.K. Trade Agreement. "It should prove easier to overcome these challenges with the UK as an individual negotiating partner."
Supporters of the National Health Service (NHS), which fixes drug prices based on their value through the National Institute for Health and Care Excellence (NICE) and currently pays PS18 billion ($23 billion) per year for medications, warned that a Trump-Johnson deal would send prices skyrocketing, drastically cutting NHS's funding for doctors and nurses.
"Today's revelations are yet more evidence that U.S. big pharma companies are lining up to cash-in on a toxic Johnson-Trump deal," said Shadow Health Secretary Jonathan Ashworth. "These mega corporations want us to pay more for medicine and the proposed U.S.-U.K. deal could draw PS500 million [$655 million] a week from our NHS."
"A Labour government will stop our NHS being sold off in a toxic trade deal with Trump," Labour Party leader Jeremy Corbyn tweeted.
U.S. control over drug prices "would hit the Scottish NHS incredibly hard," said Hannah Bardell, a Scottish National Party politician.
The Mirror reported on the documents shortly after Trump said at the NATO summit in London that the U.S. had no interest in changing how NHS operates as part of a post-Brexit trade deal.
Kevin Maguire, associate editor of the Mirror, tweeted the new evidence shows "Trump's lying, again."
Johnson's secretary of state, Dominic Raab, also confirmed Tuesday that the U.S. would be given control over life-saving drug prices in the event of a deal, saying, "The Americans will take their decisions."
"Boris Johnson has put our NHS up for sale," tweeted the Labour Party. "It's time to save the NHS from a U.S. trade deal. You can't trust the Tories with our NHS."